CTSO vs. NPCE, DCTH, PROF, DRTS, ARAY, CLPT, HSAQ, CVRX, QIPT, and TELA
Should you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include NeuroPace (NPCE), Delcath Systems (DCTH), Profound Medical (PROF), Alpha Tau Medical (DRTS), Accuray (ARAY), ClearPoint Neuro (CLPT), Health Sciences Acquisitions Co. 2 (HSAQ), CVRx (CVRX), Quipt Home Medical (QIPT), and TELA Bio (TELA). These companies are all part of the "surgical & medical instruments" industry.
NeuroPace (NASDAQ:NPCE) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.
NeuroPace has a net margin of -45.61% compared to NeuroPace's net margin of -75.07%. NeuroPace's return on equity of -129.89% beat Cytosorbents' return on equity.
NeuroPace presently has a consensus target price of $15.67, indicating a potential upside of 126.72%. Cytosorbents has a consensus target price of $2.00, indicating a potential upside of 122.20%. Given Cytosorbents' stronger consensus rating and higher probable upside, equities analysts plainly believe NeuroPace is more favorable than Cytosorbents.
Cytosorbents has lower revenue, but higher earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
In the previous week, NeuroPace had 1 more articles in the media than Cytosorbents. MarketBeat recorded 4 mentions for NeuroPace and 3 mentions for Cytosorbents. NeuroPace's average media sentiment score of 1.19 beat Cytosorbents' score of 0.87 indicating that Cytosorbents is being referred to more favorably in the news media.
78.8% of NeuroPace shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 22.2% of NeuroPace shares are held by company insiders. Comparatively, 6.6% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Cytosorbents received 412 more outperform votes than NeuroPace when rated by MarketBeat users. Likewise, 79.13% of users gave Cytosorbents an outperform vote while only 55.81% of users gave NeuroPace an outperform vote.
NeuroPace has a beta of 2.06, meaning that its stock price is 106% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.
Summary
NeuroPace beats Cytosorbents on 11 of the 18 factors compared between the two stocks.
Get Cytosorbents News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytosorbents Competitors List
Related Companies and Tools
